Narcolepsy is characterized by several symptoms that include cataplexy, excessive daytime sleepiness, hallucinations, and sleep paralysis. In addition, patients suffering from narcolepsy experience automatic behaviors such as eating, walking, or driving, in a dazed manner. Symptoms differ from patient to patient, and are diagnosed between the ages of 7 and 25.
The global narcolepsy drugs market accounted for around $2,429 million in 2018, and is expected to reach $5,360 million by 2026, registering a CAGR of 10.3% from 2019 to 2026.
Although narcolepsy is a rare and underdiagnosed chronic condition, many cases have been reported of the people affected by this disease. It was estimated that more than 1 in 2,000 people in the U.S. were affected by narcolepsy in 2012. Increase in severity of the disease and rise in the number of people being affected by narcolepsy are some of the key driving factors of the market.
Furthermore, the availability of reimbursement for FDA-approved prescription medicines is expected to fuel the demand for these drugs. However, lack of awareness regarding the diagnosis and treatment availability hinders the market growth. Conversely, increase in the number of programs by various organizations to spread awareness regarding the importance of early narcolepsy diagnosis is anticipated to offer lucrative opportunities for market expansion.
The global narcolepsy drugs market is segmented based on disease type, therapeutics type, and geography. Depending on disease type, the market is categorized into daytime extreme sleepiness, cataplexia, and others. By therapeutics type, it is segregated into central nervous system stimulants, tricyclic antidepressants, sodium oxybate, selective serotonin reuptake inhibitor, and others. Region wise, the market is examined across North America, Europe, Asia-Pacific, and LAMEA.
Comprehensive competitive analysis and profiles of major market players such as Ligand Pharmaceuticals, Addrenex Pharmaceuticals, Shire Plc., Teva Pharmaceutical Industries Ltd., Arena Pharmaceuticals, Jazz Pharmaceuticals Plc., Bioprojet, and Graymark Healthcare, Inc. have been provided in this report. Product launch and technological advancements are the few strategies adopted by the key players of the global narcolepsy drugs market.
KEY BENEFITS FOR STAKEHOLDERS
ü This report highlights the market dynamics to understand the global narcolepsy drugs market and capitalize on the prevailing opportunities.
ü Quantitative analysis of the current market and forecasts assists stakeholders to design business strategies accordingly.
ü Porter's five forces analysis examines the competitive market structure and provides a deeper understanding of the influencing factors for entry and expansion.
ü Pin-point analysis of geographical segments offers identification of most profitable segments to capitalize on.
KEY MARKET SEGMENTS
• By Disease Type
o Daytime Extreme Sleepiness
o Cataplexia
o Others
• By Therapeutics Type
o Central Nervous System Stimulants
o Tricyclic Antidepressants
o Sodium Oxybate
o Selective Serotonin Reuptake Inhibitor
o Others
• By Region
o North America
• U.S.
• Canada
• Mexico
o Europe
• Germany
• France
• Spain
• Italy
• UK
• Rest of Europe
o Asia-Pacific
• Australia
• Japan
• India
• China
• Rest of Asia-Pacific
o LAMEA
• Brazil
• Saudi Arabia
• South Africa
• Rest of LAMEA
KEY MARKET PLAYERS
• Ligand Pharmaceuticals
• Addrenex Pharmaceuticals
• Shire Plc.
• Teva Pharmaceutical Industries Ltd.
• Arena Pharmaceuticals
• Jazz Pharmaceuticals Plc.
• Bioprojet
• Graymark Healthcare, Inc.
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market Definition and Scope
3.2. Parent Market Overview
3.3. Key Forces Shaping Narcolepsy Drugs Market
3.3.1. Moderate bargaining power of suppliers
3.3.2. Low bargaining power of buyers
3.3.3. Low threat of new entrants
3.3.4. Moderate threat of substitutes
3.3.5. Moderate intensity of rivalry
3.4. Pricing Analysis
3.4.1. Pricing Analysis, By Region, 2018 & 2025
3.5. Market Evolution
3.6. Value Chain Analysis
3.7. Impact of government regulations on global narcolepsy drugs market
3.8. Patent Analysis
3.8.1. By Region
3.8.2. By Applicant
3.9. Market Dynamics
3.9.1. Drivers
3.9.1.1. Increase in global prevalence of narcolepsy
3.9.1.2. Narcolepsy awareness programs and services
3.9.1.3. Presence of reimbursement policies regarding narcolepsy
3.9.2. Restraints
3.9.2.1. Adverse effects and risks related to narcolepsy drugs
3.9.2.2. Delayed diagnosis or misdiagnosis
3.9.3. Opportunity
3.9.3.1. Untapped markets in the developing countries
CHAPTER 4: NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Daytime Extreme Sleepiness
4.2.1. Key market trends and opportunities
4.2.2. Market size and forecast
4.2.3. Market analysis, by country
4.3. Cataplexia
4.3.1. Key market trends and opportunities
4.3.2. Market size and forecast
4.3.3. Market analysis, by country
4.4. Other Disease Type
4.4.1. Key market trends and opportunities
4.4.2. Market size and forecast
4.4.3. Market analysis, by country
CHAPTER 5: NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE
5.1. Overview
5.1.1. Market size and forecast
5.2. Central Nervous System Stimulants
5.2.1. Market size and forecast
5.2.2. Market analysis, by country
5.3. Tricyclic Antidepressants
5.3.1. Market size and forecast
5.3.2. Market analysis, by country
5.4. Sodium Oxybate
5.4.1. Market size and forecast
5.4.2. Market analysis, by country
5.5. Selective Serotonin Reuptake Inhibitor
5.5.1. Market size and forecast
5.5.2. Market analysis, by country
5.6. Other Therapeutic Type
5.6.1. Market size and forecast
5.6.2. Market analysis, by country
CHAPTER 6: NARCOLEPSY DRUGS MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends and opportunities
6.2.2. North America market size and forecast, by disease type
6.2.3. North America market size and forecast, by therapeutic type
6.2.4. North America market size and forecast, by country
6.2.4.1. U.S. market size and forecast, by disease type
6.2.4.2. U.S. market size and forecast, by therapeutic type
6.2.4.3. Canada market size and forecast, by disease type
6.2.4.4. Canada market size and forecast, by therapeutic type
6.2.4.5. Mexico market size and forecast, by disease type
6.2.4.6. Mexico market size and forecast, by therapeutic type
6.3. Europe
6.3.1. Key market trends and opportunities
6.3.2. Europe market size and forecast, by disease type
6.3.3. Europe market size and forecast, by therapeutic type
6.3.4. Europe market size and forecast, by country
6.3.4.1. Germany market size and forecast, by disease type
6.3.4.2. Germany market size and forecast, by therapeutic type
6.3.4.3. France market size and forecast, by disease type
6.3.4.4. France market size and forecast, by therapeutic type
6.3.4.5. UK market size and forecast, by disease type
6.3.4.6. UK market size and forecast, by therapeutic type
6.3.4.7. Italy market size and forecast, by disease type
6.3.4.8. Italy market size and forecast, by therapeutic type
6.3.4.9. Spain market size and forecast, by disease type
6.3.4.10. Spain market size and forecast, by therapeutic type
6.3.4.11. Rest of Europe market size and forecast, by disease type
6.3.4.12. Rest of Europe market size and forecast, by therapeutic type
6.4. Asia-Pacific
6.4.1. Key market trends and opportunities
6.4.2. Asia-Pacific market size and forecast, by disease type
6.4.3. Asia-Pacific market size and forecast, by therapeutic type
6.4.4. Asia-Pacific market size and forecast, by country
6.4.4.1. Japan market size and forecast, by disease type
6.4.4.2. Japan market size and forecast, by therapeutic type
6.4.4.3. China market size and forecast, by disease type
6.4.4.4. China market size and forecast, by therapeutic type
6.4.4.5. Australia market size and forecast, by disease type
6.4.4.6. Australia market size and forecast, by therapeutic type
6.4.4.7. India market size and forecast, by disease type
6.4.4.8. India market size and forecast, by therapeutic type
6.4.4.9. South Korea market size and forecast, by disease type
6.4.4.10. South Korea market size and forecast, by therapeutic type
6.4.4.11. Rest of Asia-Pacific market size and forecast, by disease type
6.4.4.12. Rest of Asia-Pacific market size and forecast, by therapeutic type
6.5. LAMEA
6.5.1. Key market trends and opportunities
6.5.2. LAMEA market size and forecast, by disease type
6.5.3. LAMEA market size and forecast, by therapeutic type
6.5.4. LAMEA market size and forecast, by country
6.5.4.1. Brazil market size and forecast, by disease type
6.5.4.2. Brazil market size and forecast, by therapeutic type
6.5.4.3. Saudi market size and forecast, by disease type
6.5.4.4. Saudi market size and forecast, by therapeutic type
6.5.4.5. South Africa market size and forecast, by disease type
6.5.4.6. South Africa market size and forecast, by therapeutic type
6.5.4.7. Rest of LAMEA market size and forecast, by disease type
6.5.4.8. Rest of LAMEA market size and forecast, by therapeutic type
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Market Share Analysis of Top Players, 2018 (%)
7.3. Product Mapping of Top Players
7.4. Competitive Heatmap
CHAPTER 8: COMPANY PROFILES
8.1. ARENA PHARMACEUTICAL, INC.
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Business performance
8.2. BIOPROJET PHARMA SARL
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.3. JAZZ PHARMACEUTICAL PLC
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Operating segments
8.3.5. Business Performance
8.3.6. Key strategic moves and developments
8.4. LIGAND PHARMACEUTICALS INCORPORATED
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Business performance
8.5. NOVARTIS INTERNATIONAL AG
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Business performance
8.6. SHINOGI INC.
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.7. TAKEDA PHARMACEUTICAL COMPANY
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Business performance
8.8. TEVA PHARMACEUTICAL INDUSTRIES LTD.
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance